About us

Reviva Pharmaceuticals

We are a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases.

Our pipeline currently has two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house using our chemical genomics driven technology platform.

We have been granted composition of matter patents for both RP5063 and R1208 in the United States (U.S.), Europe, and several other countries.

Brilaroxazine: The Potential Future Standard of Care for Schizophrenia

Our lead drug candidate, brilaroxazine, is in clinical development for multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder, major depressive disorder (MDD), behavioral and psychotic symptoms in Alzheimer’s disease, Parkinson’s disease psychosis, and attention deficit hyperactivity disorder (ADHD). Our primary focus is to complete the clinical development of brilaroxazine for the treatment of acute and maintenance schizophrenia.

In October 2023, we announced positive topline results and successful completion of our pivotal Phase 3 RECOVER trial evaluating the efficacy, safety and tolerability of once-daily brilaroxazine in adults with schizophrenia. The RECOVER trial met all primary and secondary endpoints with statistically significant and clinically meaningful reductions across all major symptom domains at week 4 with 50 mg of brilaroxazine compared to placebo. Importantly, we have now seen generally consistent, clinically significant efficacy and safety findings across our Phase 2 REFRESH and Phase 3 RECOVER trials further reinforcing brilaroxazine’s competitive profile.

Our Commitment

We are focused on advancing our pipeline of novel medicines that may have a profound impact on the lives of those affected by these medical conditions.